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Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for
Progressive Disease and Adverse Cardiac Events in the US Population
Kevin G. Friedman, MD; Kimberly Gauvreau, ScD; Akiko Hamaoka-Okamoto, MD; Alexander Tang, BS; Erika Berry, MS;
Adriana H. Tremoulet, MD, MAS; Vidya S. Mahavadi, MD; Annette Baker, MSN, PNP; Sarah D. deFerranti, MD; David R. Fulton, MD;
Jane C. Burns, MD; Jane W. Newburger, MD, MPH
Background-—The natural history of coronary artery aneurysms (CAA) after intravenous immunoglobulin (IVIG) treatment in the
United States is not well described. We describe the natural history of CAA in US Kawasaki disease (KD) patients and identify
factors associated with major adverse cardiac events (MACE) and CAA regression.
Methods and Results-—We evaluated all KD patients with CAA at 2 centers from 1979 to 2014. Factors associated with CAA
regression, maximum CA z-score over time (zMax), and MACE were analyzed. We performed a matched analysis of treatment effect
on likelihood of CAA regression. Of 2860 KD patients, 500 (17%) had CAA, including 90 with CAA z-score >10. Most (91%) received
IVIG within 10 days of illness, 32% received >1 IVIG, and 27% received adjunctive anti-inﬂammatory medications. CAA regression
occurred in 75%. Lack of CAA regression and higher CAA zMax were associated with earlier era, larger CAA z-score at diagnosis,
and bilateral CAA in univariate and multivariable analyses. MACE occurred in 24 (5%) patients and was associated with higher CAA
z-score at diagnosis and lack of IVIG treatment. In a subset of patients (n=132) matched by age at KD and baseline CAA z-score,
those receiving IVIG plus adjunctive medication had a CAA regression rate of 91% compared with 68% for the 3 other groups (IVIG
alone, IVIG ≥2 doses, or IVIG ≥2 doses plus adjunctive medication).
Conclusions-—CAA regression occurred in 75% of patients. CAA z-score at diagnosis was highly predictive of outcomes, which may
be improved by early IVIG treatment and adjunctive therapies. ( J Am Heart Assoc. 2016;5:e003289 doi: 10.1161/
JAHA.116.003289)
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K awasaki disease (KD) is an acute vasculitis that prefer-entially affects medium-sized arteries, particularly the
coronary arteries (CA).1-3 CA involvement can range from
transient mild dilatation or ectasia, occurring in up to 40% of
patients, to giant coronary artery aneurysms (CAA).4,5 In the
pre–intravenous immunoglobulin (IVIG) era, CAA occurred in
20% to 25% of KD patients.6 With IVIG therapy, persistent
CAAs are considerably less common but still occur in 4% to
6% of patients, with 1% developing giant CAA7-9 using 1984
Japanese Ministry of Health criteria (absolute CA dimension
≥8 mm).10 The incidence of coronary abnormalities is greater
using z-score criteria.4,8,11,12 A recent, 2-center US study
found that 2.6% of patients met the z-score deﬁnition for giant
aneurysms (any CA segment with z≥10).8 Patients with large
or giant CAAs are at risk for cardiac events including CA
thrombosis or stenosis, myocardial infarction (MI), ventricular
tachycardia, and death.6,13–15 Large case series of Japanese
patients with giant CAA have shown good overall survival but
high cardiac event rates.6,13,15
The long-term natural history of CAA after treatment with
IVIG in the US population is not well described. Many patients
have regression of CAA to normal internal lumen diameter as
a result of luminal myoﬁbroblastic proliferation and layering of
thrombus in larger CAA.16 A large Japanese study from the
pre-IVIG era analyzed serial angiograms in KD patients with
CAA and showed that 55% to 60% have CAA regression,
typically within 1 to 2 years of the acute illness.6 In the US
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population, only small cohorts of patients with large and giant
CAA have been reported,14,17,18 limiting the ability to assess
risk factors associated with persistent CAA and major adverse
cardiac events (MACE). The aims of this study were to
describe the natural history of CAA in a contemporary cohort
of US KD patients and to identify factors associated with
MACE and CAA regression.
Methods
Subjects
In this 2-center retrospective study, we reviewed all patients
with KD managed at Boston Children’s Hospital and Rady
Children’s Hospital, San Diego, between 1979 and 2014. We
included all patients with CAA at any time in their illness. We
deﬁned CAA as left anterior descending coronary artery (LAD)
and/or right coronary artery (RCA) z-score >3 or original
Japanese Ministry of Health and Welfare criteria for CAA in CA
segments for which z-scores are not available (CA dimension
>3 mm for patients <5 years of age and >4 mm in patients
≥5 years of age).2 Left main CA (LMCA) z-score was not used
for inclusion due to previously reported variability in LMCA
anatomy and measurement.2,11,19 Of the 500 patients
included, 498 were included based on z-score criteria, and
2 by Japanese Ministry of Health criteria. There were no
patients in the data base with isolated LMCA CAA. Second
episodes of KD were excluded, deﬁned as repeat episode of
complete or incomplete KD after complete resolution of the
previous episode, or presence of congenital heart disease,
except for bicommissural aortic valve, mitral valve prolapse,
and hemodynamically insigniﬁcant ventricular septal defects.
Demographic, clinical, and cardiac imaging data were
collected from medical records. Clinical data included
Figure 1. Patient selection. CAA indicates coronary artery aneurysm; CHD, congenital
heart disease; IVIG, intravenous immunoglobulin; KD, Kawasaki disease; MACE, major
adverse cardiac events.
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demographics, date of KD onset, treatment center, KD
diagnostic criteria met, and KD treatment. First-line treatment
for KD at both participating institutions since 1986 has been
IVIG (2 g/kg) and aspirin. IVIG treatment was considered
delayed if given after day 10 of illness. For patients who were
IVIG-resistant, had CAA at diagnosis (CA z-score >3 or
Japanese Ministry of Health Criteria), and/or were deemed to
be at high risk by clinical criteria,20,21 second-line therapy has
varied over time and by site and has included repeat IVIG
(2 g/kg), oral or intravenous steroids (varying dosing and
duration regimens), inﬂiximab, cyclosporine, and/or
cyclophosphamide.22–27 Patients with giant CAA (CA z-score
≥10 or absolute dimension >8 mm) were chronically antico-
agulated with either warfarin or low-molecular-weight heparin.
This study was conducted with approval from the Committee
for Clinical Investigation at Children’s Hospital Boston and the
Institutional Review Board at Children’s Hospital Boston and
Rady Children’s Hospital with requirement for consent waived.
Imaging Data
Echocardiographic data were collected from reports pro-
duced at the time of the study. We collected CA measure-
ments for the following segments: LMCA, proximal and distal
LAD, circumﬂex, proximal and distal RCA, and posterior
descending CA. Using the reported measurements, we
calculated z-scores for the proximal LAD and proximal RCA
using z-score equations derived from previously described
normative data.4 Prior studies from our institution have
shown high inter- and intraobserver reliability for proximal
LAD and RCA measurement.11,19 In cases where additional
imaging modalities were performed, including cardiac mag-
netic resonance imaging, cardiac computed tomography, or
cardiac catheterization, CA dimensions were collected from
reports produced at the time of the study. The z-scores for
the proximal RCA and proximal LAD were recalculated for all
subjects using the echo-derived CA z-score formula for the
respective CA segment. We classiﬁed CAA as small (z-
score=3.0-4.9), moderate (z-score=5-9.9), or giant (z-score
≥10).12 The zMax was deﬁned as the higher value between
RCA and LAD z-scores on each echocardiogram. Analysis
included CA size and z-score at initial echocardiogram,
maximum RCA or LAD z-score over follow-up (highest zMax),
and most recent echocardiogram.
Patient Outcomes
All patients who met inclusion/exclusion criteria were
included in analysis of MACE (Figure 1). We reviewed all
available clinical information including echocardiogram,
catheterization reports, nuclear perfusion studies, stress
Table 1. Summary of Cohorts
MACE Analysis
(n=500)
Follow-Up
(n=431)
Decade of KD episode
1977–1989,
n (%)
32 (6%) 13 (3%)
1990–1999 111 (22%) 87 (20%)
2000–2009 254 (51%) 234 (54%)
2010–2014 103 (21%) 97 (23%)
Site
Boston 316 (63%) 265 (61%)
San Diego 184 (37%) 166 (39%)
Age at fever onset, y
<1 167 (33%) 143 (33%)
1 to 4 235 (47%) 207 (48%)
≥5 98 (20%) 81 (19%)
Male sex 360 (72%) 312 (72%)
Asian race 112 (22%) 104 (24%)
Location of aneurysm
Left anterior
descending
221 (44%) 202 (47%)
Right coronary 117 (23%) 95 (22%)
Both 162 (33%) 134 (31%)
z-Score of
largest CAA
at diagnosis,
median (IQR)*
4.3 (3.4, 7.0) 4.6 (3.6–8.9)
z-Score of largest
CAA at diagnosis*
z-Score <5.0 313 (63%) 289 (67%)
z-Score ≥5, <10 97 (19%) 78 (18%)
z-Score ≥10 90 (18%) 64 (15%)
IVIG treatment
Yes 456 (91%) 431 (100%)
No 31 (6%) 0
Unknown 13 (3%) 0
If IVIG Yes, IVIG re-treatment
Yes 164/456 (36%) 148/431 (34%)
No 290/456 (64%) 282/431 (65%)
Unknown 2/456 (<1%) 1/431 (<1%)
Adjunctive anti-inflammatory medication
Yes 133 (27%) 123 (29%)
No 356 (71%) 308 (71%)
Unknown 11 (2%) 0 (0%)
IVIG indicates intravenous immunoglobulin; KD, Kawasaki disease; MACE, major adverse
cardiac event.
*Larger coronary artery between left anterior descending and right coronary artery used.
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echocardiograms, internal and external clinic notes, and
operative notes. Patients were classiﬁed as having MACE if
they had any of the following at any time point: complete
proximal CA occlusion, clinical or imaging evidence of MI,
coronary artery bypass graft (CABG), percutaneous CA
intervention (PCI), cardiac death, ventricular tachycardia, or
orthotopic heart transplant (OHT). Asymptomatic CA
stenosis was not included as MACE. The primary MACE
analysis was performed on the entire cohort of CAA
patients. A subgroup analysis for MACE was performed
using only patients treated with IVIG within 10 days of fever
onset.
Additional analyses were restricted to patients who were
treated with IVIG at one of the participating institutions and
had serial follow-up echocardiograms (≥1 study with CA
measurements after the initial diagnosis of CAA) (Figure 1).
The follow-up cohort was used to analyze factors associated
with the highest zMax over follow-up and for analysis of
time to CAA regression. To avoid selection bias in analyses
of time to regression of CAA, we excluded patients who had
CAA diagnosed >2 months after acute KD or who had
<1 year of follow-up and no CAA regression. Regression of
CAA was deﬁned on a patient basis (rather than individual
CA segment). We considered CAA regression to have
occurred when echocardiograms showed z-score <2.5 for
proximal LAD and proximal RCA as well as CA dimensions
below the thresholds for the Japanese Ministry of Health
criteria for CA segments for which z-scores are not
available.
Statistics
Demographic and clinical data are presented as count
(percentage) or median with (interquartile range) or (range) as
speciﬁed. Factors associated with MACE were analyzed using
logistic regression. Model discrimination for MACE was
assessed using the area under the receiver-operator charac-
teristic curve (c statistic). Associations with highest zMax over
follow-up were evaluated using median regression. Time to CAA
regression was estimated using the Kaplan-Meier method, with
follow-up censored at 2 years after diagnosis of CAA. Factors
associated with CAA regression were explored using the log-
rank test and Cox proportional hazards regression. All multi-
variable analyses were performed using forward selection. A
matched subgroup analysis was performed across 4 treatment
groups: single dose of IVIG, repeat IVIG (≥2 IVIG doses), single
IVIG plus adjunctive anti-inﬂammatory (inﬂiximab, steroids,
cyclosporine, etc), or both repeat IVIG (≥2 IVIG doses) and
adjunctive anti-inﬂammatory medication. Patients were
matched on CAA z-score at diagnosis (small, moderate, and
large/giant) and age at diagnosis (<1 year of age or ≥1 year of
age). Comparisons across groups were performed using the
Fisher exact test or the Kruskal-Wallis test. Time to CAA was
compared using Cox regression, with patients with only a single
Figure 2. Patient outcomes. CA indicates coronary artery; CAA, coronary artery
aneurysm; CABG, coronary artery bypass graft; MI, myocardial infarction; PCI, percutaneous
coronary artery intervention.
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dose of IVIG serving as the reference group. Analyses were
performed with SAS version 9.2 (SAS Institute, Inc, Cary, NC).
Results
Demographic and clinical data for the entire cohort (n=500)
and for the subgroup of patients who were treated with IVIG
and had follow-up imaging data (follow-up cohort, n=431) are
in Table 1. There were more patients from the more recent
era (after 2000) than earlier time periods. Patients younger
than 1 year of age comprised one-third of both cohorts. In the
follow-up cohort, the median CA z-score at diagnosis was 4.6
(IQR 3.6–8.9), with 15% having large/giant CAA. In the entire
cohort, 94% of patients were treated with IVIG. The
Table 2. Description of MACE
MACE
Age at KD,
years KD Year IVIG
Age at MACE,
y MACE Description
1 MI, OHT 2.5 1981 No 29.3 Acute KD with 6-mm bilateral CAA, represented at 29 years with
cardiomyopathy (EF 15%), severe LAD stenosis
2 MI, PCI 0.8 1982 No 21.6 Giant CAA, lost to follow-up until he presented with acute chest pain and
MI due to high-grade stenosis of proximal LAD
3 CA occlusion 1.3 1983 No 22.4 Asymptomatic LAD occlusion on surveillance catheterization
4 CA Occlusion 12.2 1984 No 33.0 Asymptomatic, incidentally found to have calcified chest mass at 33 years old,
giant/thrombosed RCA CAA
5 CA occlusion 3.8 1985 No 6.9 Asymptomatic, cath 3 years post-KD with RCA occlusion
6 MI, Death 1.1 1988 Late 1.2 Acute thrombosis and fatal MI CAA 3 weeks post-acute KD
7 MI, CABG, Death 0.6 1988 Late 0.7 Thrombosis of giant LAD CAA 8 weeks post-acute KD, failed thrombolysis and
attempted CABG
8 CA occlusion 0.5 1989 No 20.0 Asymptomatic, lost to follow-up, surveillance catheterization with occluded RCA
9 MI, CA occlusion 0.9 1990 Yes 5.2 Asymptomatic, LAD occlusion by cath with rwma on resting echocardiogram
10 MI, VT, CABG, PCI 4.1 1993 Late 6.0 Giant bilateral CAA, complete LAD occlusion, high-grade RCA stenosis with
inducible perfusion defect on dobutamine MRI
11 CABG, MI 1.3 1994 Late 4.1 Thrombotic LAD occlusion in acute phase with rwma and inducible ischemia on
dobumatine MRI
12 MI, CA occlusion 9.1 1994 No 21.2 Asymptomatic, RCA occlusion, delayed enhancement and rwma on dobutamine
MRI
13 MI 0.6 1994 Late 0.6 Acute phase LAD thrombosis with apical MI
14 MI, PCI 4.7 1995 Late 14.4 Severe stenosis of proximal LAD CAA with exertional chest pain and reversible
perfusion defect on stress MIBI
15 CABG 0.6 1997 No 11.9 RCA occlusion, severe LAD stenosis, ST elevation on exercise stress test
16 MI, CABG 1.6 1999 Late 4.5 Acute chest pain and MI due to thrombotic occlusion of giant RCA CAA
17 MI, CA occlusion 0.4 1999 Late 1.3 Asymptomatic, thrombotic LAD occlusion with apical/anterior rwma, fixed
perfusion defect and +MDE on MRI
18 PCI 0.3 2002 Late 5.4 Exertional angina at age 5 years leading to catheterization showing severe RCA
stenosis, failed attempt at RCA angioplasty
19 MI, CA occlusion 2.5 2002 Late 2.6 Thrombotic occlusion of giant circumflex CAD 1 month post-acute KD, residual
+MDE and resting rwma
20 MI, Death 0.1 2003 Yes 0.3 Giant bilateral CAA. Sudden cardiac arrest at home 10 weeks post-KD.
21 MI 0.3 2003 Late 4.7 Asymptomatic, severe RCA stenosis with rwma on rest echo and +MDE on MRI
22 CABG 9.4 2007 Yes 11.6 RCA occlusion, reversible perfusion defect on stress MIBI and inducible
rwma on stress echo
23 MI, CA occlusion 0.6 2007 Yes 0.7 Occlusive LAD thrombus and MI in acute stage treated with heparin
24 CA Occlusion 1.7 2010 Yes 0.7 LAD thrombosis in acute phase, successfully treated with thrombolytic
CAA indicates coronary artery aneurysm; CABG, coronary artery bypass graft; KD, Kawasaki disease; LAD, left anterior descending; MACE, major adverse cardiac event; MDE, myocardial
delayed enhancement; MI, myocardial infarction, MRI, magnetic resonance imaging; PCI, percutaneous coronary intervention; RCA, right coronary artery; rwma, regional wall motion
abnormality; VT, ventricular tachycardia.
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percentage of patients treated with IVIG increased over time
with 44% treated in 1977–1989, 87% treated in 1990–1999,
and 97% treated in 2000–2014 (P<0.001). Re-treatment with
IVIG (32%) and use of adjunctive anti-inﬂammatory medica-
tions (1 or more adjunctive medications given in 27% of
patients) were common. Adjunctive anti-inﬂammatory medi-
cation usage consisted of steroids in 91 patients (18%),
inﬂiximab in 69 (14%), cyclosporine in 6 (1.2%), cyclophos-
phamide in 1 (0.2%), and anakinra in 1 (0.2%) patient.
Comparisons of patient characteristics between the 2 sites
are shown in Table S1.
Patient outcomes for all 500 CAA patients are shown in
Figure 2. Of the 361 patients with adequate follow-up imaging
data, 269 (75%) had CAA regression within 2 years of KD
episode. MACE occurred in 24 patients (Table 2), 8 of whom
had known persistent CAA and 16 who did not have serial
follow-up imaging (12 followed at outside institutions and 4
lost to follow-up). No patients with CAA regression had MACE.
MACE occurred at a median age of 3.5 years (range 0.2-
29.7 years) and median time from KD of 1.5 years (range
14 days to 27 years). Median follow-up time for the entire
cohort was 11.7 years (IQR 6.9–16.6 years).
MACE included 3 deaths, 1 orthotopic heart transplant
(OHT), 6 CABG, and 2 PCI (Table 2). The deaths all occurred
in infants who had thrombosis of the LAD in the acute or
subacute period. First, a 13-month-old male 3 weeks after
illness onset suffered acute thrombosis of giant proximal LAD
CAA and fatal MI. Second, a 7-month-old male 8 weeks after
illness onset had thrombosis of a giant LAD aneurysm and
acute MI. After thrombolytic therapy failed, he was taken to
the operating room for a CABG, which was unsuccessful, and
the patient died in the early postoperative period. Third, a 6-
week-old female with giant bilateral CAA who died suddenly
at home 2.5 months into illness from presumed MI; her
family refused autopsy. One patient underwent OHT. He
developed KD at 2.5 years of age with large bilateral CAA. He
presented again at age 29 years with congestive heart failure
symptoms, high-grade LAD stenosis, and cardiomyopathy
(ejection fraction 15%). Six patients underwent CABG, and 2
underwent PCI at a median age of 6 years (range 4.1-
12.4 years) and median interval of 3 years post–acute KD
(range 1.7-11.3 years). Of the 12 patients with MI or CA
occlusion but no other MACE, 4 had clinical symptoms of MI,
and 8 had no recognized clinical symptoms and were
diagnosed on surveillance imaging (eg, radionuclear imaging,
cardiac MRI with myocardial delayed enhancement, or PET
scan).
Factors associated with MACE in univariate and multi-
variable analysis are shown in Table S2 and Table 3,
respectively. Larger CAA size at diagnosis had the highest
discrimination for prediction of MACE, with a c-statistic of
0.92. MACE occurred in 21 of 90 patients (23%) with z-score
≥10 at diagnosis, 3 of 97 (3%) with z-score of 5 to 10 at
diagnosis, and in none of 313 patients with CA z-score <5 at
diagnosis. All patients with MACE had a history of giant CAA
at some time point. The 3 patients with z-score 5 to 10 at
diagnosis who experienced MACE all had progression in size
of CAA to z-score >10 during follow-up. Lack of IVIG
Table 3. Multivariable Analysis of Factors Associated With
Major Adverse Cardiac Events
Odds Ratio P Value c-Statistic
Size of CAA at diagnosis
(for each 1 unit increase
in z-score)*
1.1 <0.001 0.93
No IVIG treatment 9.0 <0.001
CAA indicates coronary artery aneurysm; IVIG, intravenous immunoglobulin.
*Larger coronary artery between left anterior descending and right coronary artery used.
Table 4. Multivariable Analysis of Factors Associated With
Higher Maximal CA z-Score
Coefﬁcient P Value
Largest CAA size at diagnosis*
z<5.0 1.00 —
z≥5, <10 2.65 <0.001
z≥10 18.2 <0.001
CAA location
LAD or RCA alone 1.00 —
Both LAD and RCA 1.10 0.01
CA indicates coronary arteries; CAA, coronary artery aneurysm; LAD, left anterior
descending coronary artery; RCA, right coronary artery.
*Larger coronary artery between left anterior descending and right coronary artery used.
Figure 3. Kaplan-Meier curve for coronary artery aneurysm
regression: entire cohort. CAA indicates coronary artery aneur-
ysm.
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treatment was also associated with MACE in multivariable
analysis. MACE occurred in 11/44 (25%) patients who did
not receive IVIG, 9/171 (5%) patients who received IVIG
≥10 days after fever onset, and in only 4/285 (1.4%)
patients who were treated within 10 days. When follow-up
duration is included in the multivariate model, both size of
CAA at diagnosis (OR 1.1, P<0.001) and lack of IVIG
treatment (OR 4.4, P=0.03) as well as follow-up duration
(OR=1.1, P=0.02) are associated with MACE. Demographic
factors, decade of treatment, site of treatment, use of
additional IVIG doses and/or adjunctive anti-inﬂammatory
medications were not independent risk factors for MACE. In
a subgroup analysis restricted to patients who received IVIG
within 10 days of treatment, CAA size at diagnosis was the
only factor associated with MACE.
In the 431 patients with follow-up CA imaging, the highest
zMax occurred on the baseline echocardiogram, ie, at
diagnosis, in 273 patients (63%) and at follow-up in 158
patients (37%). In the latter group the median time to highest
zMax was 12 days (interquartile range 0-27 days). Median
highest zMax was 4.5 (range 3.1-29.9). Univariate and
multivariable analyses of factors associated with zMax are
shown in Table S3 and Table 4, respectively. In multivariable
analysis only larger CAA z-score at diagnosis and bilateral
CAA remained associated with higher zMax. Although IVIG re-
treatment and treatment with adjunctive anti-inﬂammatory
medications were both associated with higher zMax in
univariate analysis, additional KD treatments were not
associated with larger zMax after adjustment for baseline
CA z-score.
CAA regression to normal internal lumen diameter within
2 years occurred in 269 of 361 patients (75%) (Figure 3).
Kaplan-Meier curves (Figure 4) and Table 5 show factors
associated with CAA regression. In multivariable analysis,
lack of CAA regression was associated with earlier era, larger
CAA z-score at diagnosis, and bilateral CAA. The CAA
regression rate in the most recent 5-year period was 91%
compared with 77% from 2000 to 2009 and 49% prior to
Figure 4. Kaplan-Meier curves for coronary artery aneurysm regression. A, Decade of Kawasaki disease episode. B, IVIG treatment within
10 days of fever onset. C, Maximum coronary artery z-score at diagnosis. D, Location of coronary artery aneurysm. CAA indicates coronary
artery aneurysm; IVIG, intravenous immunoglobulin; LAD, left anterior descending coronary artery; RCA, right coronary artery.
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2000. Only 19% of patients with CAA z-score ≥10 at
diagnosis had CAA regression, whereas 55% with z-score
between 5 and 9.99 and 87% with z<5 had CAA regression.
Patients with bilateral CAA had a lower incidence of
regression (45%) than those with only LAD (86%) or RCA
(84%) CAA. IVIG re-treatment and/or use of adjunctive anti-
inﬂammatory medications were not associated with time to
CAA regression. Evaluation of CAA regression of individual CA
segments showed 458 total aneurysmal CA segments (LAD
and RCA) in the 361 patients. The regression rate was
modestly higher in LCA (211/280, 75%) compared to RCA
(119/178, 65%). When the analysis is limited to patients who
received IVIG within 10 days of fever onset (n=250), the
same risk factors remain signiﬁcant for lack of CAA
regression in multivariable analysis: earlier time period of
KD (1984-1999 HR=1.00, 2000-2009 HR=2.08, 2010-2014
HR=3.40, P<0.001); larger CAA (CAA z-score ≥10 HR=1.00,
z≥5, <10 HR=4.83 [P=0.01], z<5 HR=11.70 [P<0.001]); and
bilateral CAA (HR=0.38, P<0.001).
Finally, we analyzed the effects of treatment strategy on
likelihood of CAA regression within 2 years of disease onset
using 4 matched groups of 34 patients each, with matching
based on age group and CAA z-score at diagnosis (Table 6).
Median age (1.7-2.0 years) and CAA z-score at diagnosis
(4.2-4.4) were similar between groups. The CAA regression
rate was 91% in patients who received IVIG and adjunctive
anti-inﬂammatory medication compared to 68% in the other
3 groups (single dose of IVIG, IVIG ≥2 doses, IVIG ≥2 doses
and adjunctive anti-inﬂammatory medication) (OR=1.95,
P=0.02). Treatment strategy was collinear with site and era
of treatment and differed between comparison groups
(Table 6).
Table 5. Factors Associated With CAA Regression
n
Number (%) With
CAA Regression
Hazard
Ratio P Value
Univariate analysis 361 269 (75)
Time period of KD
1979–1999 75 37 (49) 1.00 —
2000–2009 206 159 (77) 2.13 <0.001
2000–2014 80 73 (91) 3.58 <0.001
Site
Boston 208 143 (69) 1.00 —
San Diego 153 126 (82) 1.37 0.01
Sex
Female 99 68 (69) 1.00 —
Male 262 201 (77) 1.15 0.33
Age at fever onset
≥5 y 69 52 (75) 1.00 —
1 to 4 y 178 146 (82) 1.17 0.33
<1 y 114 71 (62) 0.72 0.07
Asian race
No/unknown 269 189 (70) 1.00 —
Yes 92 80 (87) 1.47 0.004
Largest CAA size at diagnosis*
z<5.0 263 228 (87) 9.48 <0.001
z≥5, <10 62 34 (55) 3.53 0.002
z≥10 36 7 (19) 1.00 —
Size of CAA at
diagnosis (for
each 1 unit
increase in z-score)*
— — 0.87 <0.001
CAA location
Left anterior
descending
coronary artery
183 158 (86) 3.16 <0.001
Right coronary artery 81 67 (83) 2.88 <0.001
Both 97 44 (45) 1.00 —
Timing of IVIG treatment
<10 days of fever 239 191 (80) 2.06 <0.001
>10 days of fever 55 29 (53) 1.00 —
Unknown timing 67 49 (73) 1.69 0.03
IVIG re-treatment
No 234 193 (82) 1.00 —
Yes 111 71 (64) 0.65 0.002
Use of adjunctive anti-inflammatory meds
No 259 195 (75) 1.00 —
Yes 102 74 (73) 1.00 0.98
Continued
Table 5. Continued
n
Number (%) With
CAA Regression
Hazard
Ratio P Value
Multivariable analysis
Time period of KD
1977–1999 1.00 —
2000–2009 2.17 <0.001
2000–2014 3.49 <0.001
Largest CAA size at diagnosis
z<5.0 6.73 <0.001
z≥5, <10 3.00 0.009
z≥10 1.00 —
CAA location—both
RCA and LAD
0.61 0.007
CAA indicates coronary artery aneurysm; KD, Kawaski disease; IVIG, intravenous
immunoglobulin.
*Larger coronary artery between left anterior descending and right coronary artery use.
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Discussion
In this 2-center study, we describe outcomes in the largest
cohort of US KD patients with CAA reported to date. We found
an overall CAA regression rate of 75%. MACE occurred in
5% of CAA patients, almost exclusively in those with large/
giant CAA at diagnosis. Initial CA z-score was highly predictive
of CA regression, highest CA zMax over time, and clinical
events. Because echocardiograms are now routinely obtained
at diagnosis, it has become increasingly clear that initial CAA
size provides excellent risk stratiﬁcation.8,28 This study adds
to existing evidence that CAA size at diagnosis is highly
predictive of both CAA persistence and cardiac events.28,29
The CAA regression rate of 75% in our cohort is higher than
reported by prior studies.6,17,18 A large Japanese study from
the pre-IVIG era performed serial angiograms in KD patients
with CAA and showed that 55% to 60% had CAA regression,
typically within 1 to 2 years of KD.6 Notably, none of the
patients with giant aneurysms (n=26) in that study had CAA
regression. Similarly, we found that CAA size at diagnosis is
highly predictive of CAA regression rate, with a low CAA
regression rate (16%) in patients with large/giant CAA and a
high regression rate in those with small CAA at diagnosis
(85%). More aggressive therapy, particularly increased use of
repeat IVIG or additional anti-inﬂammatory medications, may
decrease CA inﬂammation and progressive dilation and
thereby account for improved CAA regression rate.26,30,31
Improved echocardiographic techniques and routine use of CA
z-scores for deﬁnition of CAA may lead to identiﬁcation of
more small CAA, and this may also contribute to the higher
CAA regression rate in our study compared to prior studies.19
MACE occurred exclusively in patients with giant CAA; 23%
of patients in this group had at least 1 MACE. The cardiac
event rate in the current study is lower than that in prior
Japanese studies, which report cardiac event-free survival
ranging from 30% to 50% in KD patients with giant
CAA.13,15,32 Possible explanations for this difference include
the deﬁnition of giant CAA; z-score >10 in this study
compared to >8 mm absolute dimension in older literature,
which uses Japanese Ministry of Health Criteria. Additionally,
more aggressive anticoagulation and medical management
may play a role in improved outcomes in this
Table 6. Matched Treatment Effect Analysis
IVIG Alone
(n=34)
IVIG92
Doses (n=34)
IVIG+Anti-inﬂammatory
(n=34)
IVIG92 Doses and
Anti-inﬂammatory (n=34) P Value
CAA regression rate 68% 68% 91% 68% 0.02
Age at fever onset, y 1.9 (0.8, 4.4) 2.0 (0.7, 4.3) 1.7 (0.6, 4.3) 1.8 (0.7, 4.0) 0.94
<1 year 12 (35%) 12 (35%) 12 (35%) 12 (35%) 1.0
≥1 year 22 (65%) 22 (65%) 22 (65%) 22 (65%)
CAA z-score at diagnosis 4.0 (3.5, 5.2) 4.3 (3.4, 5.2) 4.1 (3.4, 5.4) 3.9 (3.5, 5.0) 0.99
z-score <5.0 25 (74%) 25 (74%) 25 (74%) 25 (74%) 1.0
z-score ≥5.0, <10.0 6 (18%) 6 (18%) 6 (18%) 6 (18%)
z-score ≥10.0 3 (9%) 3 (9%) 3 (9%) 3 (9%)
Male sex 23 (68%) 29 (85%) 24 (71%) 24 (71%) 0.34
Asian race 10 (29%) 5 (15%) 10 (29%) 9 (26%) 0.44
Time period of KD <0.001
1984–1999 7 (21%) 13 (38%) 1 (3%) 5 (15%)
2000–2009 18 (53%) 19 (56%) 13 (38%) 17 (50%)
2010–2014 9 (26%) 2 (6%) 20 (59%) 12 (35%)
Treatment ≥10 days of fever 5 (21%) 2 (6%) 5 (16%) 3 (10%) 0.41
Site <0.001
Boston 17 (50%) 28 (82%) 5 (15%) 20 (59%)
San Diego 17 (50%) 6 (18%) 29 (85%) 14 (41%)
CAA location 0.79
LAD 20 (59%) 19 (56%) 20 (59%) 17 (50%)
RCA 5 (15%) 8 (24%) 7 (21%) 5 (15%)
Both LAD and RCA 9 (26%) 7 (21%) 7 (21%) 12 (35%)
CAA indicates coronary artery aneurysm; KD, Kawasaki disease; LAD, left anterior descending; RCA, right coronary artery.
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population.12,17,33 Duration of follow-up in this study was
shorter than those in Japanese studies of KD patients in the
pre-IVIG era. Conversely, 8 events were clinically silent and
were only detected on surveillance imaging showing myocar-
dial scar and/or ﬁxed perfusion defect. Importantly, absence
of IVIG administration was an independent risk factor for
MACE. In the entire cohort only 4 patients treated with IVIG
within 10 days of fever onset developed MACE, whereas 19
patients who had late or no IVIG treatment developed MACE.
This provides a strong argument that the most effective
intervention for reducing cardiac sequalae from KD involves
improved education and awareness in order to prevent missed
or delayed diagnosis of KD.34-36
Our results also suggest that KD recognition and prompt
treatment have improved over time with resultant improve-
ment in outcomes. Speciﬁcally, in the most recent 5-year
period, the CAA regression rate was90%, and there was only
1 MACE. This CAA regression rate is higher than those of prior
eras (50% to 75%) and also higher than those previously
reported.6 Improvement in outcomes may be related to greater
recognition of KD, leading to fewer patients with late and
missed diagnoses. It is also possible that better outcomes are
a consequence of more aggressive acute-phase therapies for
patients with CA abnormalities at diagnosis in the more recent
era.26,30,31 The latter hypothesis is supported by a subgroup
analysis of our patients who received IVIG within 10 days of
fever onset; those treated in the most recent 5-year period
were more likely to receive additional KD medications and had
a higher rate of CAA regression than patients treated in prior
eras. Although administration of anti-inﬂammatory medica-
tions adjunctive to IVIG was associated with improved
outcomes, our study design did not permit causal inference
and should be viewed as hypothesis generating. Future large
randomized controlled trials are needed to determine optimal
therapy in KD patients who present with CAA.
Other limitations of this study include its retrospective
design, with less optimal data capture in the early era. The
precision of our estimates of MACE was limited by losses to
follow-up and inability of young children to report symptoms,
such as MI. There is potential ascertainment bias in diagnosis
of MACE, particularly clinically silent MI, as follow-up diagnos-
tic testing and follow-up duration varied. Both centers in this
study are referral centers for management of KD with CA
complications, and this may bias the MACE rate. Many
covariates were highly correlated, eg, treatment regimen and
era, preventing causal inference. The matched analysis of
treatment effect is subject to confounding by indication; we
attempted to mitigate this by matching based on CAA size at
diagnosis. KD therapy varied over time and by site. Indications
for additional IVIG and adjunctive anti-inﬂammatory medica-
tions were not standardized over the study period. We cannot
determine if anticoagulation had an effect on CAA regression
rate or MACE in patients with giant CAA because all giant CAA
patients were on long-term anticoagulants. Because the
sample size in our matched treatment analysis was small,
we grouped all adjunctive anti-inﬂammatory medications
together and had insufﬁcient power to analyze the treatment
effect of speciﬁc anti-inﬂammatory medications or steroid
regimens. The matched analysis was further limited by the
small number of patients with large/giant CAA who could be
matched (n=5 in each group), as well as the inability to
evaluate the timing of adjunctive anti-inﬂammatory therapies
relative to disease onset. Finally, regression of lumen diameter
in CAA is not equivalent to normalization of the arterial wall,
particularly after remodeling of large and giant CAAs in which
layering thrombus and luminal myoﬁbroblastic proliferation
occur, leaving these patients at risk for cardiac events.37,38
Conclusions
In summary, in the largest cohort of US patients with KD and
CAA reported to date, 71% had CAA regression over a 2-year
period. Clinical outcomes were associated with CAA z-score at
diagnosis as well as with prompt treatment with IVIG and
adjunctive therapies. Once large/giant CAAs develop, the
risks of CAA persistence and MACE are high; early recognition
of KD and mitigation of CAA progression are thus key.28,39-41
Randomized, clinical trials of adjunctive anti-inﬂammatory
therapies for KD patients who present with CAA are needed to
improve outcomes for this vulnerable patient population.
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SUPPLEMENTAL MATERIAL
 Table S1 
 
  
  
Boston 
n=316 
San Diego 
n=184 
P Value 
Decade of KD episode 
 
 <0.001 
         1977-1989 (n, %)   31 (10%)     1   (1%)  
         1990-1999   94 (30%)   17   (9%)  
         2000-2009 136 (43%) 118 (64%)  
         2010-2014   55 (17)%   48 (26%)  
Age at Fever Onset (years)   <0.001 
        <1  109 (34%)   58 (32%)  
         1-4 131 (41%) 104 (57%)  
        ≥ 5   76 (24%)   22 (12%)  
Male Sex 230 (73%) 130 (71%) 0.61 
Asian Race   52 (16%)   60 (33%) <0.001 
Location of Aneurysm     0.007 
       Left Anterior Descending 131 (41%)   90 (49%)  
       Right Coronary   67 (21%)   50 (27%)  
       Both 118 (37%)   44 (24%)  
z-score of Largest CAA at Diagnosis (median, IQR)* 4.5 [3.5, 9.4] 4.0 [3.4-5.2] <0.001 
z-score of Largest CAA at Diagnosis*   <0.001 
        z-score < 5.0 179 (57%) 134 (73%)  
        z-score ≥ 5, < 10   63 (20%)   34 (18%)  
 IVIG, intravenous immunoglobulin  
*Larger coronary artery between left anterior descending and right coronary artery used. 
 
 
 
 
 
 
 
 
 
 
        z-score ≥ 10   74 (23%)   16   (9%)  
IVIG Treatment   0.30 
         Yes 285 (90%) 171 (93%)  
         No 20 (6%)   11   (6%)  
         Unknown 11 (4%)     2   (1%)  
If IVIG Yes, IVIG retreatment     <0.001 
          Yes 129/285 (45%)   35/171 (20%)  
          No 155/285 (54%) 135/171 (79%)  
          Not reported 1  1  
Adjunctive Anti-Inflammatory Medication   <0.001 
          Yes   71 (22%)   62 (34%)  
          No 245 (78%) 112 (61%)  
          Not reported     0   (0%)   10   (5%)  
KD, Kawasaki Disease; CAA, coronary artery aneurysm; IVIG, intravenous immunoglobulin 
* Larger coronary artery between left anterior descending and right coronary artery used. 
  
Table S2. Univariate Analysis of Factors Associated with 
Major Adverse Cardiac Events 
 
  
Odds Ratio p-
value 
c-statistic 
Decade of KD 
 
 0.73 
   1977-1989 14.5 <0.001  
   1990-1999 3.4 0.02  
   2000-2014 1.0 --  
Site Boston 2.3 0.11 0.58 
Asian Race 0.14 0.06 0.60 
Bilateral CAA 3.1 0.008 0.64 
Size of CAA at Diagnosis (for each 1 unit   
    increase in z-score)* 
1.1   
<0.001 
0.92 
Largest CAA z-score at Diagnosis ≥10* 41.3 <0.001 0.87 
No IVIG Treatment 11.9 <0.001 0.67 
Adjunctive Anti-Inflammatory Medication 2.0 0.11 0.58 
 Table S3. Univariate Analysis of Factors Associated 
with Higher Maximal CA Z-score 
  
n Median 
Zmax 
IQR p-value 
Time Period of KD 
 
  0.16 
   1979-1999 100 5.1 3.7, 11.2  
   2000-2009 234 4.6 3.6, 8.9  
   2000-2014 97 4.2 3.4, 6.0  
Site  
 
  0.02 
    Boston 265 4.8 3.7, 11.0  
    San Diego 166 4.3 3.5, 6.2  
Sex    0.06 
    Female 119 4.9 3.7, 11.0  
    Male 312 4.5 3.5, 7.8  
Age at Fever Onset    <0.001 
   < 1 year 143 5.5 3.8, 12.1  
    1-4 years 207 4.2 3.5, 6.0  
    ≥ 5 years 81 4.4 3.5, 6.9  
Asian Race    0.009 
    Yes 104 4.4 3.4, 5.5  
     No/unknown 327 4.6 3.7, 10.1  
Largest CAA size at 
Diagnosis* 
 
  <0.001 
    z< 5.0 289 3.9 3.4, 4.6  
    z≥ 5, <10 78 7.0 5.7, 10.9  
    z≥ 10 64 22.7 15.3, 31.2  
CAA Location    <0.001 
   LAD 202 3.9 3.4, 5.0  
   RCA 95 3.9 3.4, 4.9  
   Both  134 10.3 5.6, 20.4 --- 
Timing of IVIG Treatment    0.008 
   ≤ 10 days of fever 273 4.4 3.5, 7.0  
   >10 days of fever 71 6.0 3.8, 16.1  
   Unknown timing 87 4.6 3.7, 9.8  
IVIG retreatment    <0.001 
    No 255 4.1 3.4, 5.2  
    Yes 130 5.8 3.9, 14.3  
Use of Adjunctive Anti-    <0.001 
CA, coronary artery; KD, Kawasaki Disease; CAA, coronary artery aneurysm; LAD, left anterior descending coronary 
artery; RCA, right coronary artery IVIG, intravenous immunoglobulin 
* Larger coronary artery between left anterior descending and right coronary artery used  
 
 
 
Inflammatory Meds 
   No 308 4.3 3.5, 6.4  
   Yes 123 5.6 4.2, 14.5  
